Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The invention provides compounds of formula (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A material carrying mechanism includes a base, a tray and an adjustment assembly. The tray is movably mounted on the base, and the adjustment assembly is mounted on the base. The adjustment assembly includes a first ejection member and a first elastic restoring member. The first ejection member includes a first telescopic portion abutting against the tray. The first telescopic portion can perform a telescopic movement in a first direction to push the tray to move in the first direction. The first elastic restoring member is connected between the base and the tray, so as to provide to the tray a restoring force directed to the first ejection member.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A method and apparatus for estimating a rotor position of a motor, and a motor control system. The method includes: obtaining a position error signal by injecting a high-frequency signal into a stator winding of the motor; obtaining a load parameter indicating a load of the motor, obtaining a direct-current component disturbance value according to the load parameter and a first preset relationship, obtaining a harmonic component disturbance value according to the load parameter and a second preset relationship, and obtaining an observer parameter value according to the load parameter and a third preset relationship; compensating the position error signal according to the direct-current component disturbance value and the harmonic component disturbance value to obtain a compensated position error signal; adjusting an observer parameter according to the observer parameter value, and adjusting the compensated position error signal through an adjusted observer to obtain the rotor position and a rotor speed.

Abstract: A method and apparatus for estimating a rotor position of a motor, and a motor control system. The method includes: obtaining a position error signal by injecting a high-frequency signal into a stator winding of the motor; obtaining a load parameter indicating a load of the motor, obtaining a direct-current component disturbance value according to the load parameter and a first preset relationship, obtaining a harmonic component disturbance value according to the load parameter and a second preset relationship, and obtaining an observer parameter value according to the load parameter and a third preset relationship; compensating the position error signal according to the direct-current component disturbance value and the harmonic component disturbance value to obtain a compensated position error signal; adjusting an observer parameter according to the observer parameter value, and adjusting the compensated position error signal through an adjusted observer to obtain the rotor position and a rotor speed.

Abstract: The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia.

Abstract: The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia.

Abstract: The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia.